View:
Mini BasicThis view is available after user registration.
ShortThis view is available when you buy a license.
StandardThis view is available when you buy a license.
CompleteThis view is available when you buy a license.
Pertuzumab (840/420) / Trastuzumab (8/6) / Palbociclib 125 / Fulvestrant 500, Breast Cancer, Cycle 1
Protocol-ID: 3112 V1.0 (Mini), PERT(840/420)/TRAS(8/6)/PALB125/FLVS500, Breast Ca, C1Indication(s)
- Breast Cancer; ICD-10 C50.-
HER2+ & HR+
Links
- Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer (PATINA) [clinicaltrials.gov]
- PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib 1 Anti-HER2 therapy 1 endocrine therapy (ET) vs. anti-HER2 therapy 1 ET after induction treatment for hormone receptor positive (HR1)/HER2-positive metastatic breast cancer (MBC) [URL]
 | The publishers and authors assume no liability for the accuracy of the contents. The application is at the own responsibility of the treating physician. ©Onkopti. |
Valid since: 07.02.2026